Specific depletion of the FRβ+ subpopulation of TAMs in vivo using CAR-T cell therapy results in reprogramming of the TME, promotion of endogenous T cell-mediated immunity and control of tumor progression, and synergizes with a tumor antigen-targeted CAR-T cell therapy when applied as a preconditioning regimen. The gene discussed is FOLR2; the disease is neoplasm.